IL1B and hydrops fetalis: The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial randomized 10,061 patients with prior AMI and residual inflammation; canakinumab, a humanized IL-1β antibody or placebo given once every 3 months, subcutaneously showed to significantly reduce HF hospitalizations and HF-related mortality [62••].